Monitoring antiviral resistance in patients receiving nucleos(t)ide analog therapies for hepatitis B: Which method should be used?

Journal of Hepatology

Volumn 48, Issue 6, 2008, Pages 892-894

  Degertekin, Bulent ^a   Lok, Anna S ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ENTECAVIR; LAMIVUDINE; NUCLEOTIDE; TELBIVUDINE;

EDITORIAL; GENE AMPLIFICATION; GENE MUTATION; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIVIRAL AGENTS; DNA, VIRAL; DRUG MONITORING; DRUG RESISTANCE, VIRAL; GENETIC PREDISPOSITION TO DISEASE; GUANINE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MUTATION; NUCLEOSIDES; NUCLEOTIDES; PHENOTYPE;

EID: 43049167514     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.03.010     Document Type: Editorial

References (31)

1. Lok A.S., Lai C.L., Leung N., Yao G.B., Cui Z.Y., Schiff E.R., et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125 (2003) 1714-1722
2. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131 (2006) 1743-1751
3. Colonno R.T., Rose R.E., Pokornowski K., Baldick C.T., and Eggers B. Four year assessment of ETV resistance in nucleoside-naive and lamivudine refractory patients. J Hepatol 46 (2007) S294
4. Lai C., Gane E., Hsu C.W., Thongsawat S., and Wang Y. Two-year results from the globe trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) vs. lamivudine. Hepatology 46 (2007) 63A
5. Fung S.K., Chae H.B., Fontana R.J., Conjeevaram H., Marrero J., Oberhelman K., et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 44 (2006) 283-290
6. Villet S., Pichoud C., Villeneuve J.P., Trepo C., and Zoulim F. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 131 (2006) 1253-1261
7. Yim H.J., Hussain M., Liu Y., Wong S.N., Fung S.K., and Lok A.S. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 44 (2006) 703-712
8. Lok A.S., Zoulim F., Locarnini S., Bartholomeusz A., Ghany M.G., Pawlotsky J.M., et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 46 (2007) 254-265
9. Lai C.L., Chien R.N., Leung N.W., Chang T.T., Guan R., Tai D.I., et al. A one-year trial of lamivudine for chronic hepatitis B. Asia hepatitis lamivudine study group. N Engl J Med 339 (1998) 61-68
10. Dienstag J.L., Schiff E.R., Wright T.L., Perrillo R.P., Hann H.W., Goodman Z., et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341 (1999) 1256-1263
11. Chang T.T., Gish R.G., de Man R., Gadano A., Sollano J., Chao Y.C., et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354 (2006) 1001-1010
12. Lai C.L., Gane E., Liaw Y.F., Hsu C.W., Thongsawat S., Wang Y., et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 357 (2007) 2576-2588
13. Lai C.L., Shouval D., Lok A.S., Chang T.T., Cheinquer H., Goodman Z., et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354 (2006) 1011-1020
14. Kim H.S., Han K.H., Ahn S.H., Kim E.O., Chang H.Y., Moon M.S., et al. Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization. Antivir Ther 10 (2005) 441-449
15. Lok A.S., Zoulim F., Locarnini S., Mangia A., Niro G., Decraemer H., et al. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J Clin Microbiol 40 (2002) 3729-3734
16. Hussain M., Fung S., Libbrecht E., Sablon E., Cursaro C., Andreone P., et al. Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir. J Clin Microbiol 44 (2006) 1094-1097
17. Allen M.I., Gauthier J., DesLauriers M., Bourne E.J., Carrick K.M., Baldanti F., et al. Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine. J Clin Microbiol 37 (1999) 3338-3347
18. Tran N., Berne R., Chann R., Gauthier M., Martin D., Armand M.A., et al. European multicenter evaluation of high-density DNA probe arrays for detection of hepatitis B virus resistance mutations and identification of genotypes. J Clin Microbiol 44 (2006) 2792-2800
19. Yeh C.T., Chien R.N., Chu C.M., and Liaw Y.F. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 31 (2000) 1318-1326
20. Bozdayi A.M., Uzunalimoglu O., Turkyilmaz A.R., Aslan N., Sezgin O., Sahin T., et al. YSDD: a novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine. J Viral Hepat 10 (2003) 256-265
21. Borroto-Esoda K., Miller M.D., and Arterburn S. Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. J Hepatol 47 (2007) 492-498
22. Lacombe K., Ollivet A., Gozlan J., Durantel S., Tran N., Girard P.M., et al. A novel hepatitis B virus mutation with resistance to adefovir but not to tenofovir in an HIV-hepatitis B virus-co-infected patient. Aids 20 (2006) 2229-2231
23. Schildgen O., Sirma H., Funk A., Olotu C., Wend U.C., Hartmann H., et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 354 (2006) 1807-1812
24. Curtis M., Zhu Y., and Borroto-Esoda K. Hepatitis B virus containing the I233V mutation in the polymerase reverse-transcriptase domain remains sensitive to inhibition by adefovir. J Infect Dis 196 (2007) 1483-1486
25. Sheldon J., Camino N., Rodes B., Bartholomeusz A., Kuiper M., Tacke F., et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 10 (2005) 727-734
26. Delaney IV W.E., Ray A.S., Yang H., Qi X., Xiong S., Zhu Y., et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother 50 (2006) 2471-2477
27. Baldick C.J., Eggers B.J., Fang J., Levine S.M., Pokornowski K.A., Rose R.E., et al. Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response. J Hepatol 48 (2008) 895-902
28. Tenney D.J., Levine S.M., Rose R.E., Walsh A.W., Weinheimer S.P., Discotto L., et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 48 (2004) 3498-3507
29. Zoulim F. In vitro models for studying hepatitis B virus drug resistance. Semin Liver Dis 26 (2006) 171-180
30. Colonno R.J., Rose R., Baldick C.J., Levine S., Pokornowski K., Yu C.F., et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 44 (2006) 1656-1665
31. Lai C.L., Leung N., Teo E.K., Tong M., Wong F., Hann H.W., et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129 (2005) 528-536